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EPIDEMIOLOGY AND PREVENTION
Intimate Partner Violence and Adherence to HIV
Pre-exposure Prophylaxis (PrEP) in African Women in HIV
Serodiscordant Relationships: A Prospective Cohort Study
Sarah T. Roberts, MPH,* Jessica Haberer, MD, MS,†‡ Connie Celum, MD, MPH,*§k
Nelly Mugo, MBChB, MPH,§¶ Norma C. Ware, PhD,‡# Craig R. Cohen, MD, MPH,**
Jordan W. Tappero, MD, MPH,†† James Kiarie, MBChB, MPH,‡‡ Allan Ronald, MD,§§
Andrew Mujugira, MBChB, MSc,* Elioda Tumwesigye, MBChB, MSc,kk Edwin Were, MBChB, MPH,¶¶
Elizabeth Irungu, MBChB, MPH,## and Jared M. Baeten, MD, PhD,*§k for the Partners PrEP Study Team
Background: Intimate partner violence (IPV) is associated with
higher HIV incidence, reduced condom use, and poor adherence to
antiretroviral therapy and other medications. IPV may also affect
adherence to pre-exposure prophylaxis (PrEP).
Methods: We analyzed data from 1785 HIV-uninfected women
enrolled in a clinical trial of PrEP among African HIV serodiscordant
couples. Experience of verbal, physical, or economic IPV was
assessed at monthly visits by face-to-face interviews. Low PrEP
adherence was defined as clinic-based pill count coverage ,80% or
plasma tenofovir levels,40 ng/mL. The association between IPV and
low adherence was analyzed using generalized estimating equations,
adjusting for potential confounders. In-depth interview transcripts
were examined to explain how IPV could impact adherence.
Results: Sixteen percent of women reported IPV during a median
of 34.8 months of follow-up (interquartile range 27.0–35.0). Overall,
7% of visits had pill count coverage ,80%, and 32% had plasma
tenofovir ,40 ng/mL. Women reporting IPV in the past 3 months
had increased risk of low adherence by pill count (adjusted risk ratio
1.49, 95% confidence interval: 1.17 to 1.89) and by plasma tenofovir
(adjusted risk ratio 1.51, 95% confidence interval: 1.06 to 2.15).
Verbal, economic, and physical IPV were all associated with low
adherence. However, the impact of IPV diminished and was not
statistically significant 3 months after the reported exposure. In
qualitative interviews, women identified several ways in which IPV
affected adherence, including stress and forgetting, leaving home
without pills, and partners throwing pills away.
Conclusions: Women who reported recent IPV in the Partners
PrEP Study were at increased risk of low PrEP adherence. Strategies
to mitigate PrEP nonadherence in the context of IPV should
be evaluated.
Key Words: intimate partner violence, pre-exposure prophylaxis,
adherence, HIV prevention
(J Acquir Immune Defic Syndr 2016;73:313–322)
INTRODUCTION
Randomized trials have demonstrated that oral antiretro-
viral pre-exposure prophylaxis (PrEP) is effective for HIV
prevention in several populations, including heterosexual men
and women,1,2 men who have sex with men,3–5 and injection
drug users.6 Based on these data, the World Health Organization
recommends PrEP as part of a comprehensive HIV prevention
package for people at substantial risk of HIV infection.7 Several
PrEP demonstration projects are testing strategies to maximize
population impact and cost-effectiveness.8,9
One population eligible for PrEP targeting is sexually
active women in sub-Saharan Africa.10 In this region, women
have considerably higher incidence of HIV than do men,
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particularly at young ages.11 Intimate partner violence (IPV)
is also common, with lifetime prevalence estimates ranging
from 36% to 71%.12 IPV is associated with an increased risk
of HIV infection,13–20 with 2 prospective studies showing that
HIV incidence is approximately 50% higher among women
who have experienced IPV than women with no IPV
history.21,22 In the study by Kouyoumdjian et al,22 the effect
size was similar for physical, sexual, and verbal IPV;
increased with IPV frequency and severity; and persisted
for more than 1 year after the last violent episode. In the
context of violent relationships, individual-level biomedical
interventions such as PrEP may be more effective for HIV
prevention than behavioral interventions requiring coopera-
tion of both partners.22,23 However, for PrEP to prevent HIV
infection, consistently high adherence is necessary during
periods of potential exposure.24–26 Women who experience
IPV have lower adherence to several medication regimens,
including antiretroviral therapy (ART) for HIV treatment and
methadone treatment for drug addiction27–30; IPV may also be
a barrier to PrEP adherence.31
With programs or demonstration projects beginning to
offer PrEP to women, including women who experience IPV, it
is important to understand whether adherence levels will be
high enough for PrEP to be effective. If IPV is associated with
low PrEP adherence, additional, targeted adherence support
may be required for IPV survivors. We conducted a prospective
cohort study to examine whether recent and/or past exposure to
IPV is associated with low PrEP adherence among HIV-
uninfected women participating in a clinical trial of PrEP.
METHODS
Study Population
The population for this analysis was all HIV-uninfected
women participating in the Partners PrEP Study, a phase 3,
randomized, double-blind, placebo-controlled clinical trial
that demonstrated the efficacy of daily oral PrEP among
HIV-uninfected members of HIV serodiscordant couples. The
design, procedures, and outcomes of the trial are described
elsewhere.1,32 Briefly, from 2008 to 2012, 4747 couples were
randomized and followed at 9 research sites in Kenya and
Uganda. HIV-uninfected partners were randomly assigned to
once-daily tenofovir disoproxil fumarate (TDF), emtricitabine
(FTC)/TDF, or placebo, and followed monthly for 12–48
months. All couples received a package of HIV prevention
services, including risk-reduction counseling, couples’ coun-
seling, and condoms. The study protocol was approved by the
University of Washington Human Subjects Review Commit-
tee and ethics review committees at each of the study sites.
All participants provided written informed consent in English
or their local language.
Data Collection
Experience of IPV was assessed monthly by asking
whether the participant had been verbally, physically, or
economically abused by her partner since the last study visit.
Participants were asked in the context of a risk-reduction
counseling session, in local languages, and in a manner
considered culturally appropriate for each study site.33
Although the wording of the question varied and was context
specific, all interviewers were experienced in counseling
couples and were trained through multiple role plays to
assess and document IPV on case report forms according to
standard protocols. If the participant reported IPV, the type
(verbal, physical, or economic), frequency, and consequences
(eg, relationship breakup, income loss) were documented on
a structured questionnaire.
PrEP adherence was measured by clinic-based pill
counts and plasma tenofovir concentrations. For all HIV-
uninfected participants, pill counts were conducted on
returned, unused medication tablets each month at the study
clinic. Plasma samples were collected and stored at visit
months 1, 3, and quarterly thereafter, and at any visit during
which a participant tested positive for HIV. Plasma tenofovir
concentrations were measured only in a subset of participants,
using ultraperformance liquid chromatography–mass spec-
trometry assay methods.34 Of the 1297 plasma tenofovir
measurements, 606 (47%) were from 113 randomly sampled
women, and 691 (53%) were from 302 women purposively
selected for other secondary analyses.32,34–37
Demographic characteristics were collected separately
from the participant and her partner at enrollment, including
age, income, education, weekly alcohol intake, marital status,
relationship duration, and how long the couple had known
they were serodiscordant. Data on sexual behavior, including
coital frequency, condom use, and outside partnerships were
collected through interviewer-administered questionnaires
at monthly intervals for the participants and at quarterly
intervals for their partner. We relied on participant reports for
dyad-level data such as relationship duration and coital
frequency, and on partner reports for his individual-level
data, including demographic characteristics and outside
partnerships. Monthly HIV testing and annual STI testing
were conducted using methods described previously.38
Data Analysis
At each study visit, women were categorized as having
no IPV reported to date in the study, IPV reported in the past
3 months, or IPV reported in the study and .3 months ago.
This approach enabled us to distinguish between an acute
effect of recent IPV on PrEP adherence, compared with
a more long-lasting effect.
Pill count coverage was defined as the percentage of
days between study visits when a pill was available to be taken,
calculated as: (number of pills dispensed 2 number of pills
counted)/number of days between study visits. Coverage was
dichotomized into high ($80%) or low (,80%), consistent
with other HIV prevention studies39,40 and with recent
pharmacodynamic modeling suggesting that 6 of 7 doses per
week of oral FTC/TDF PrEP may be required to protect female
genital tissue from HIV infection.41 Although clinic-based pill
counts are an imperfect measure of adherence, they were
strongly correlated with other objective measures of adherence
in the Partners PrEP Study.30,31 Visits were excluded if the
participant was not taking the study drug for a protocol-defined
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reason, such as pregnancy, breastfeeding, seroconversion, or
toxicity concerns. Missed visits were included, because one
possible consequence of IPV could be failure to attend clinic
visits, and adherence was set to zero when the number of days
since the last visit exceeded the number of pills dispensed.
About 2% (1400/59,806) of eligible follow-up visits
were missed.
Plasma tenofovir adherence was dichotomized at 40 ng/
mL. This concentration is based on the lower 95% confidence
interval 24 hours after dose for directly observed daily dosing
at steady state, but is also consistent with a single dose taken
in the last 24 hours.42–45 We selected this threshold because it
is more sensitive to occasional missed doses than a threshold
of detectable versus nondetectable, and because data suggest
that near-daily dosing may be necessary to achieve adequate
vaginal concentrations of activated intracellular metabolites
of tenofovir diphosphate and FTC triphosphate required for
effective protection from HIV.46,47
We evaluated the associations between IPV and each
PrEP adherence measure using univariate and multivariable
(adjusted) generalized estimating equation Poisson models
with an exchangeable correlation matrix and robust standard
errors, to account for repeated measures for each partici-
pant.48,49 Multivariable models were adjusted a priori for
age, study site, and time in study. We also evaluated the
following covariates as potential confounders and retained
them in the model if they resulted in meaningful changes
(.10%) to the estimated risk ratios: baseline covariates of
partnership duration, years in the known HIV serodiscordant
partnership, age difference with HIV-infected partner,
income, education, alcohol intake; and time-varying cova-
riates of HIV-infected partner’s report of outside sexual
partners, and participant’s reports of outside sexual partners
and any sex with their HIV-infected partner. Because
changes in the participant’s sexual behavior could be either
a cause or a consequence of IPV, the last 2 time-varying
covariates were lagged by 3 months to ensure that they
preceded both the exposure and the outcome. Because the
amount of missing data was small (,5% of visits), we
conducted complete case analyses. Risk estimates did
not change under different assumptions about the values of
missing data. In sensitivity analyses, we excluded partic-
ipants with pill count coverage .103%, indicating that
fewer pills were returned than would be expected based
on the number of days since the last visit. Previous studies
suggest that coverage above that threshold may indicate
lower adherence.34,50 To maximize statistical power,
we included measurements from both randomly sampled
and purposefully sampled participants in our plasma
tenofovir analysis. We also restricted the analysis to
randomly sampled participants to assess the potential for
selection bias.
Additional analyses examined the effects of the type of
IPV (physical, verbal, or economic) and the frequency of
physical and verbal IPV on PrEP adherence measured by pill
count coverage. The comparison group for each of these
analyses was women who reported no IPV to date in the
study. We used a Cox proportional hazards model to
determine whether IPV was associated with higher HIV
incidence in this cohort. The adjusted hazard ratios (aHRs)
controlled for study arm and did not change with adjustment
for age, marital/cohabiting status, number of children, any sex
or unprotected sex in past month, male partner viral load and
circumcision status, HSV-2 status at enrollment, or depot
medroxyprogesterone acetate (DMPA) use.
Qualitative Data
As part of an ancillary adherence substudy, in-depth
qualitative interviews were conducted with 88 HIV-
uninfected participants (40 women and 48 men) at a single
study site in Uganda. Methods and other findings from these
interviews are described elsewhere.51,52 Participants were
purposively sampled based on adherence levels, as estimated
from unannounced home-based pill counts conducted as part
of the substudy procedures. The study enrolled all 58
participants at the site whose adherence dropped below
80% at some point during the substudy (“low adherers”),
and a sample of 30 participants with 100% adherence
throughout the substudy (“perfect adherers”). Women in the
qualitative sample were older than in the overall study [age:
median 36 years, interquartile range (IQR) 29.5–40.5], had
fewer years of schooling (median 3, IQR 0–5), and were more
likely to earn an income (97.5%). They were similar to the
overall sample on marital status, relationship duration, and
number of children. The interview addressed participants’
experiences of taking PrEP, accounts of missed doses and
lapses in adherence, and strategies for sustaining adherence.
Interviews were conducted a minimum of 3 months and
median of 21 months after enrollment (IQR 16–24 months).
Data were analyzed using an inductive process to understand
social influences that seemed to impact adherence. For this
analysis, we reviewed the 7 transcripts that contained
references to IPV, including 4 low adherers and 3 perfect
adherers. Relevant content was organized to reveal patterns in
the data. The ancillary adherence substudy was approved by
the Partners Health Care Human Research Committee, the
University of Washington Human Subjects Review Commit-
tee, and the Uganda National Council on Science and
Technology. Separate written consent was obtained from all
participants for this substudy.
RESULTS
Participant Characteristics
Characteristics of the 1785 HIV-uninfected female
participants are shown in Table 1. Mean age was 33.2 years;
participants had completed an average of 5.6 years of school;
and 69.6% had earned any income in the past 3 months. The
majority of participants were married (99.2%), with a mean
relationship duration of 12.9 years, and had mutually
disclosed HIV serodiscordant status for a mean of 1.4 years.
Prevalence and Correlates of IPV
Over the course of the study, 288 women (16.1%)
reported IPV at 437 visits (0.7% of 60,191 total visits). Of
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these women, 198 (68.8%) reported IPV at 1 study visit,
19.8% at 2 visits, 6.6% at 3 visits, and 4.9% at $4 visits.
Most women reported multiple types of IPV (Fig. 1A). Verbal
IPV was the most common, reported at 376 visits, followed
by physical IPV (235 visits) and economic IPV (212 visits).
At 53% of visits with verbal IPV, women reported 1–2
incidents since the last monthly study visit. Three to 5 incidents
were reported at 31% of visits, and$6 incidents at 15%. At the
majority of visits with physical IPV (86%), women reported 1–
2 incidents since the last visit, with 13% reporting 3–5
incidents and 3% reporting $6 incidents (Fig. 1B). The most
common consequences of IPV were change of residence,
relationship loss, and income/property loss. Missed doses of
study drug and missed study visits were also reported, although
these were not predetermined response categories and were
mentioned infrequently (Fig. 1C).
Women who reported IPV were similar to women who
reported no IPV on most demographic, relationship, and
behavioral characteristics (Table 1). Baseline characteristics
associated with subsequent reporting of IPV included having
TABLE 1. Participant Characteristics at Baseline and During Follow-up
Enrollment, Mean (SD) or n (%) N Total (N = 1785)
Any IPV in Study
(n = 288)
No IPV in Study
(n = 1497) P*
Demographic and relationship characteristics
Age, yrs 1785 33.2 (7.5) 32.6 (7.2) 33.4 (7.6) 0.08
Partner age, yrs 1785 39.2 (8.1) 38.2 (8.2) 39.4 (8.0) 0.03
Age difference (participant age 2 partner age) 1785 6.0 (6.0) 5.7 (6.3) 6.0 (5.9) 0.4
Ugandan (versus Kenyan) 1785 1203 (67.4%) 216 (75.0%) 987 (65.9%) 0.003
Years of school 1785 5.6 (3.8) 5.4 (3.7) 5.6 (3.8) 0.4
Any income 1785 1242 (69.6%) 255 (78.1%) 1017 (67.9%) 0.001
Married 1785 1770 (99.2%) 286 (99.3%) 1484 (99.1%) 0.8
Partnership duration, yrs 1711 12.9 (8.3) 12.2 (7.7) 13.0 (8.4) 0.1
Years known discordant 1781 1.4 (1.7) 1.6 (1.6) 1.3 (1.7) 0.02
No. children 1785 3.9 (2.2) 3.8 (2.2) 3.9 (2.2) 0.6
Behavioral characteristics
No. drinks per week 1785 0.2 (0.9) 0.3 (0.8) 0.2 (0.9) 0.3
No. sex acts with study partner, past month 1785 5.5 (5.0) 6.0 (6.2) 5.4 (4.7) 0.1
Unprotected sex with study partner, past month 1785 406 (22.8%) 69 (24.0%) 337 (22.5%) 0.6
Sex with outside partner, past month 1785 8 (0.5%) 0 (0.0%) 8 (0.5%) 0.2
Male partner reports outside partner, past month 1785 264 (14.8%) 44 (15.3%) 220 (14.7%) 0.8
Any STI diagnosis† 1636 221 (13.5%) 32 (12.2%) 189 (13.8%) 0.5
Follow-up (Per Person) N Total (N = 1785)
Any IPV in Study
(n = 288)
No IPV in Study
(n = 1497) P*
No. visits 1785 33.7 (9.4) 35.7 (8.4) 33.3 (9.6) ,0.001
Duration of follow-up, mo 1785 31.2 (8.3) 33.0 (7.4) 30.9 (9.5) ,0.001
No. visits reporting IPV 288
1 — 198 (68.8%) — —
2 — 57 (19.8%) — —
3 — 19 (6.6%) — —
4 or more — 14 (4.9%) — —
Ever pregnant 1785 397 (22.2%) 57 (19.8%) 340 (22.7%) 0.3
Any STI diagnosis† 1781 258 (14.5%) 51 (17.7%) 207 (13.9%) 0.09
HIV seroconversion 1781 57 (3.2%) 9 (3.1%) 48 (3.2%) 0.9
Follow-up (Per Visit) N
Total
(N = 58,406 Visits)
Any IPV‡
(n = 419 Visits)
No IPV
(n = 57,987 Visits) P*
No. sex acts with study partner, past month 57,439 3.7 (4.1) 3.5 (5.3) 3.7 (4.1) 0.4
Any sex with study partner, past month 57,439 46,538 (81.0%) 288 (68.7%) 46,250 (81.1%) ,0.001
No. unprotected sex acts, past month 57,439 0.5 (1.9) 1.0 (3.7) 0.4 (1.8) 0.001
Any unprotected sex with study partner, past month 57,439 7111 (12.4%) 94 (22.4%) 7017 (12.3%) ,0.001
Outside sexual partner, past month 58,384 1329 (2.3%) 13 (3.1%) 1316 (2.3%) 0.3
Male partner reports outside partner, past month 55,310 8069 (14.8%) 79 (19.8%) 7990 (14.8%) 0.005
*P values are based on t tests with unequal variance for continuous variables and Pearson x2 tests for categorical variables.
†Any positive test result for chlamydia, gonorrhea, syphilis, or trichomonas. At enrollment, 149 women were missing 1 or more sexually transmitted infection (STI) tests at
enrollment and had no positive tests.
‡IPV was reported at 437 total visits, of which 18 were enrollment visits and 419 were follow-up visits.
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younger partners (mean 38.2 versus 39.4 years), having
mutually disclosed HIV serodiscordant status for slightly
longer (1.6 versus 1.3 years), and reporting any income
(78.1% versus 67.9%). Seventy-five percent of women who
reported IPV were from Uganda (versus Kenya), compared
with 65.9% of women who did not report IPV in the study. At
visits with IPV, women were less likely to report sexual
activity with their study partners than at visits with no IPV
(68.7% versus 81.1%), more likely to report unprotected sex
(22.4% versus 12.3%), and more likely to have partners who
reported an outside sexual partner (19.8% versus 14.8%).
Adherence to PrEP and Association With IPV
Pill count coverage was high among most women,
regardless of reported IPV [mean 95.3%, standard deviation
(SD) 19.8%, Table 2]; the proportion of visits with pill
count coverage ,80% was 7.0%. Among visits with plasma
tenofovir measurements, 32.0% had concentrations
,40 ng/mL.
Table 3 presents crude and adjusted risk ratios (aRRs)
for the association of IPV with PrEP adherence. After
adjusting for age, study site, time on study, and male partner
reports of outside sex partners, women were 50% more likely
to have low PrEP adherence at visits with IPV in the past 3
months, compared with visits with no IPV to date in the
study. This association was consistent regardless of whether
adherence was measured by pill count [aRR = 1.49, 95%
confidence interval (CI): 1.17 to 1.89, P = 0.001] or by
plasma tenofovir (aRR = 1.51, 95% CI: 1.06 to 2.15, P =
0.02). Adherence at visits .3 months after reported IPV was
similar to adherence at visits with no IPV to date in the study
(aRR for pill count: 1.08, 95% CI: 0.86 to 1.36, P = 0.5, aRR
for plasma tenofovir: 0.95, 95% CI: 0.73 to 1.24, P = 0.7).
There was no evidence of effect modification by time on
study, or by country for recent IPV; for IPV occurring in the
study .3 months ago, lower adherence persisted in Kenya
but not in Uganda (P interaction = 0.02) in the pill count
analysis but not in the plasma tenofovir analysis.
The association between IPV in the past 3 months and
low adherence was similar in women who reported sex in the
past month (aRR = 1.53, 95% CI: 1.11 to 2.10, P = 0.009)
and women who reported no sex in the past month (aRR =
1.44, 95% CI: 1.04 to 1.99, P = 0.03). Risk estimates did not
substantially change when pill count analyses excluded
participants with coverage .103%, when tenofovir analyses
were restricted to the randomly sampled cohorts, or when
adjusting for other potential confounding factors listed
in Methods.
When different types of IPV were considered sepa-
rately, effect sizes for pill count coverage were similar for
recent (past 3 month) verbal IPV (aRR = 1.65, 95% CI: 1.17
to 2.33, P = 0.005) and recent economic IPV (aRR = 1.48,
95% CI: 1.14 to 1.92, P = 0.003). The effect of recent
physical IPV was not statistically significant (aRR = 1.27,
95% CI: 0.89 to 1.82, P = 0.2). However, the frequency of
IPV since the last study visit was higher for verbal IPV (mean
4.1 episodes, SD 6.9) than for physical IPV (mean 1.7
episodes, SD 2.1), and the risk of low adherence increased
significantly with increasing frequency of recent physical IPV
(aRR = 1.09 for each additional episode of IPV within the
reporting period, 95% CI: 1.04 to 1.14, P, 0.001) and recent
verbal IPV (aRR = 1.02 for each additional episode, 95% CI:
1.02 to 1.03, P, 0.001). Type and frequency of IPV reported
FIGURE 1. Descriptive statistics for IPV exposure during the
study. A, Type of IPV reported at each study visit in which any
IPV was reported. B, The number of IPV episodes reported
since the last study visit. Data were not collected on frequency
of economic IPV. C, Reported consequences of IPV. Con-
sequences marked with an asterisk (*) were explicitly listed as
response options, whereas those without the asterisk were
described by participants in the open-ended “other” category.
Participants were only asked to describe IPV consequences
during follow-up visits. Data are missing for the IPV episodes
reported at enrollment.
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in the study and .3 months ago were not associated
with adherence.
IPV and HIV Incidence
There were 48 HIV seroconversions among women
with no IPV to date in the study, 9 among women with
IPV during the study and .3 months ago, and 2 among
women with IPV in the past 3 months, resulting in HIV
incidence rates of 1.2, 1.3, and 2.2 per 100 person-years,
respectively. The associations between IPV and HIV
incidence were not statistically significant (aHR for IPV
in the past 3 months: 1.54, 95% CI: 0.37 to 6.51, P = 0.6;
aHR for IPV .3 months ago: 1.26, 95% CI: 0.55 to 2.90,
P = 0.6).
Participant Reports on IPV and PrEP Use
Although the in-depth interviews did not specifically
ask about IPV, 7 women raised the topic when describing
adherence challenges and strategies. Three patterns of how
IPV interfered with adherence were evident in the transcripts
(Table 4). Some women explained how violence and discord
in the home made it difficult to remember to take the pills
(panel A in Table 4). Others described running away during
violent episodes, either because they feared for their safety or
because they were chased away by their partners; they did not
take their pills with them when leaving the house, so these
episodes could result in missed doses (panel B in Table 4). In
2 cases, the women’s partners threatened to take or throw
away their pills, either as a form of punishment or because
they blamed relationship discord on the pills themselves
(panel C in Table 4). Some women also described ways to
surmount these challenges, and maintained high adherence
despite experiences of IPV. Two women reported sending
their children to retrieve their pills after they had run away
from the house, and another was able to replace pills her
husband had thrown away by explaining her situation to the
study staff (panel D in Table 4).
DISCUSSION
Overall, adherence to PrEP was high among women in
the Partners PrEP Study, regardless of the IPV history.
However, women who reported IPV in the past 3 months
had an increased risk of low PrEP adherence. The association
did not persist for more than 3 months after the violence
occurred, which suggests that, among this group of women, the
effects of IPV on adherence were acute and time-limited.
Qualitative findings suggested several pathways through which
IPV may cause short-term adherence lapses, including stress,
being forced to leave the home, or a partner trying to take pills
away from the participant; some women also developed
strategies to maintain high adherence during IPV episodes.
This is the first study to examine the association between
IPV and PrEP adherence. IPV was associated with less
frequent use of condoms and diaphragms in one prospective
study53 and with lower ART uptake, self-reported ART
adherence, and viral suppression in a meta-analysis.27 Other
studies have described the importance of partner support and
disclosure of product use for good adherence in PrEP and
microbicide trials,52,54–59 and the role of violence as a barrier to
disclosure.57,59 Because couples enrolled in the Partners PrEP
Study together, our findings suggest that IPV impacts adher-
ence even when women are using PrEP with their partner’s
knowledge and consent. It will be important for PrEP
demonstration projects targeting high-risk women to collect
data on this risk factor going forward.
At 16%, the period prevalence of IPV during this study
was similar to that reported in another study of HIV
TABLE 2. Summary of Adherence by Measure and IPV Status
Adherence Measure
Pill Count Coverage (%) Plasma Tenofovir Levels
No. Visits Mean (SD) ,80%, n (%) No. Visits ,40 ng/mL, n (%)
IPV in study, #3 mo ago 1100 95.5 (18.7) 88 (8.0) 38 16 (42.1)
IPV in study, .3 mo ago 5471 94.8 (21.5) 433 (7.9) 142 40 (35.2)
No IPV to date in study 43,562 95.5 (19.6) 2962 (6.9) 1117 349 (31.2)
Total 50,165 95.3 (19.8) 3510 (7.0) 1297 415 (32.0)
TABLE 3. Effect of IPV Exposure on Each PrEP Adherence Outcome: Univariate and Multivariable Results
Pill Count Coverage ,80% Tenofovir ,40 ng/mL
Risk Ratio
(95% CI) P
Adjusted* Risk
Ratio (95% CI) P
Risk Ratio
(95% CI) P
Adjusted* Risk
Ratio (95% CI) P
IPV in study, #3 mo ago 1.28 (1.03 to 1.59) 0.03 1.49 (1.17 to 1.89) 0.001 1.41 (1.01 to 1.99) 0.05 1.51 (1.06 to 2.15) 0.02
IPV in study, .3 mo ago 1.27 (1.05 to 1.54) 0.02 1.08 (0.86 to 1.36) 0.5 1.15 (0.91 to 1.45) 0.3 0.95 (0.73 to 1.24) 0.7
No IPV to date in study 1.00 — 1.00 — 1.00 — 1.00 —
*Adjusted for age (years), study site, time on study (days), and whether male partner reports outside sex partner.
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serodiscordant couples using the same instrument,33 but lower
than national Demographic and Health Survey estimates of
spousal violence in the past 12 months: 41% in Kenya and
45% in Uganda.60,61 Our study population consisted of women
in stable long-term relationships who were willing to be tested
for HIV with their partners and to enroll in a couples-based
prevention study. Women with these characteristics may be
less likely to experience IPV than women in the general
population or those participating in other PrEP trials. Several
qualitative studies have noted the predominance of violence in
the lives of PrEP and microbicide study participants in some
geographies, such as for some women in South Africa where
the majority of VOICE and FEM-PrEP participants resided.62,63
Our estimates of the impact of IPV on PrEP adherence may be
based on more moderate or infrequent IPV, and the effect may
be stronger or more persistent in other populations. However,
women reporting IPV in our study population reported higher
risk sexual behavior, such as unprotected sex and having
a partner who reported outside partners, relationship loss,
change of residence, and property loss, which suggests that
they experienced meaningful consequences of IPV.
Strengths of this study include a large sample size,
prospective study design, and integration of quantitative and
qualitative methods. Our findings were robust to different
measures of PrEP adherence, adjustment for multiple poten-
tial confounding factors, and several sensitivity analyses to
address misclassification, missing data, and selection bias.
The association between recent IPV and PrEP adherence
persisted when we restricted the analysis to women reporting
sexual activity with their study partners, which suggests that
IPV increases the risk of low adherence during periods in
which women are at risk for HIV acquisition. Although the
study was not powered to test for an association between IPV
and HIV incidence, the hazard ratio point estimates are
consistent with previous estimates of a 50% increase in HIV
incidence associated with IPV.21,22,33
An important limitation to our study is that classification
of IPV was based on self-report and may be underreported. Our
measurement tool did not ask about sexual IPV, violence
severity, history of IPV before enrollment, or specific violent
acts such as hitting, slapping, or threatening. Women may not
have disclosed IPV if they did not consider specific acts to be
abusive or if they did not feel comfortable discussing IPV with
the study staff. In addition, IPV was assessed in the context of
a counseling session rather than with a standardized question.
This approach may have increased disclosure of IPV, but IPV
assessment may have differed between sites. We cannot
distinguish whether differences in reported IPV and its effects
represent true differences in the rate of IPV by site or country,
differences in participant willingness to report IPV, or differ-
ences in IPV ascertainment by study interviewers. If the degree
of underreporting is the same among women with low versus
high PrEP adherence, this would likely underestimate the risk
of low adherence associated with IPV. Although the proportion
TABLE 4. Excerpts From Qualitative Interviews on How IPV Impacts PrEP Adherence
Pattern Example
A) Stress Now when you don’t have peace or you have slept outside, can’t the day end when you are embroiled in quarrels and forget
about the drugs?—participant QLA028
If the family is not fine and there is no cooperation between you and your husband, that eventually affects the way one swallows
his/her medicine. But if the home is okay and there is peace, even the children will be allowed to remind you—participant
QLA055
B) Leaving home without
study drug
Of course I go without drugs. Now if we fight and I run away, can I go with the drugs? Or I just run for safety and look for refuge
somewhere?—participant QLA 028
The whole of December and November, I was in serious problems; I could not remember to swallow medicine.he would chase
me out of the house and I would not get a chance to take my medicine with me. He would chase me and I spend the nights in
the middle of nowhere; sometimes in church or in the bush.it was hard for me to remember to swallow medicine. Our
relationship was not good; it was a very difficult moment in our relationship—participant QLA 055
We fought, my husband and I, so I ran away to my parents’ home. In the process, I left the bottles behind—participant QPA 002
It’s hard for me to remember each and every day I missed. But one common reason that has led me to miss my medicine on
several occasions is.; My husband likes taking alcohol. And when he drinks, he becomes violent. There are times when he
chase me and I run out of the house. Sometimes, that happens before I swallow the medicine and you find that I don’t have
a chance to go back—participant QLA 053
C) Partner throws away or
threatens to take study
drugs
.there is some problem that happened where we quarreled at home and he threw away my drugs.He was telling me that; “let
me throw away these pills and we will remain the same because it seems they are the ones making you behave like that. He had
taken some alcohol which was forcing him to behave like that—participant QPA 020
He was saying that since I refused to use condoms, he would also swallow my drugs.We quarreled over it, he chased me and I
slept in the kitchen, from there I never looked back, I went back to my parents.—participant QPA 016
D) Resilience When my child brought me what to put on in the morning, he also carried my drug bottles along. The man was busy staging
a roadblock carrying a panga that I should not dare step in the house looking for clothes, while the children bypassed him and
entered the bedroom where they picked clothes and drugs and brought them to me. So ever since I started taking the drugs, I
have never stopped or missed taking them—participant QPA 016
It is my son who sneaked the bottles out of the house and brought them to me. My husband had actually locked everything in the
bedroom. So I told my son to devise all means possible to get for me my pill bottles—participant QPA 002
.he threw away my drugs, but I gathered them again and when the study staff came to visit us, I explained to them. They told
me to come to the clinic the following day and get more drug—participant QPA 020
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of visits with low adherence was higher when measured by
plasma tenofovir levels than by pill count coverage, the risk
estimates for IPV and PrEP adherence were consistent between
adherence measures, increasing our confidence in the results.
Although the qualitative interviews were conducted at only one
study site, a review of the narrative descriptions of IPV
episodes and consequences on study case report forms suggest
that the mechanisms described were relevant to other sites in
Uganda and to Kenya as well.
In sub-Saharan Africa, targeting PrEP to high-risk
women may be a cost-efficient approach to reduce HIV
incidence,64–66 but high adherence levels are required during
periods of risk. Demonstration projects are ongoing to evaluate
the feasibility of this approach and to identify strategies for
implementation.67–69 Given the high prevalence of IPV in this
region, and its impact on HIV risk, IPV should be considered
when identifying high-risk women. In our cohort, the majority
of women were able to take PrEP consistently, regardless of
IPV history, but IPV in the short-term was associated with
lower adherence in some subjects. Efforts to target PrEP
toward women with IPV should recognize the risk of low
adherence, and interventions should be evaluated to promote
PrEP adherence in the context of violence. A potential
intervention could integrate lessons from successful PrEP
adherence programs70 and from interventions to improve
ART adherence among HIV-infected women with histories
of abuse,71 and could include motivational interviewing and
problem-solving approaches to help women identify ways that
IPV impacts their adherence and develop approaches to
prevent violence or avoid lapses in adherence associated with
IPV.70,71 Individual or group counseling approaches should be
evaluated; group counseling may involve a social support
network that could increase self-efficacy for adherence.72 Some
women in our study reported strategies to maintain adherence
in the face of IPV, and lessons from these examples of
resilience could help in developing successful interventions.
Such interventions could increase the prevention benefit of
PrEP by promoting effective use in a population at high risk
of HIV.
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